Ann: FDA Technegas Approval Webinar, page-33

Yes agree. It's painful to watch and hard to know how you get interest when volume is so unbelievably low. The numbers aren't going to explode immediately and will take time although I'm hoping the trajectory looks good quickly. I imagine there'll have to be some growing interest as the next dividend approaches but that is months away unfortunately. It's unfortunate too that this time around the biotech market is particularly bad. Keep pumping the narrative of Beyond PE being greatly facilitated by US approval. That's where the story gets more exciting!